Saturday, July 22, 2023

EffIciency Of Neurometabolic Therapy Among the Patients with Ischemic Hemispheric Stroke In Recovery Period

FYI.

EffIciency Of Neurometabolic Therapy Among the Patients with Ischemic Hemispheric Stroke In Recovery Period

©O. A. Kozyolkin, S. O. Medvedkova, A. A. Kuznietsov
Zaporizhzhia State Medical University
Summary. Cerebrovascular diseases, and especially their acute forms, cerebral strokes, are an important problem in modern medicine.
The search and usage of new and more effective drugs, which contribute to the improvement of treatment results in the recovery period of the disease, are relevant.
the aim of the study – to improve the treatment of patients with cerebral ischemic stroke in the recovery period by using phenylpiracetam in the complex therapy.
 
Materials and Methods. 
The work presents the results of treatment of 70 patients (average age is (58.8±0.9) years) in the recovery
period of ischemic hemispheric stroke (IHS). All the patients were divided into two clinical groups of 35 patients. The group 1 included the patients who received phenylpiracetam in a complex therapy orally in a daily dose of 200 mg, divided into 2 intakes: in the morning and at lunch for 30 days; the group 2 consisted of patients who received piracetam as a nootropic drug parenterally in a daily dose of 3000 mg once in the morning during 30 days. All the patients were carried out in the dynamics before the treatment and after 30 days the assessment of the state according to the stroke scale of the National Institute of Health in order to determine the severity of the stroke. The degree of functional restoration according to Modified Rankin Scale and the estimation of the ability of household skills and self-service according to the Barthel Index were determined. A dynamic evaluation of cognitive impairments was performed using the Mini-Menthal State Examination and the 10-word memory test. 
Results and Discussion. 
As a result of treatment, positive dynamics of all clinical-neurological and cognitive indicators was observed, it was more revealed in patients of the main group using phenylpiracetam, compared with the control group (p<0.05). In the main group, after the therapy, MMSE points increased by 13.0 % (p˂0.01) due to the improvement of most cognitive domains: memory in 2 times (p˂0.01), attention and calculation – by 33.3 % (p˂0.01), orientation – by 12.5 % (p˂0.01). In the control group it was registered statistically significant but less revealed, in comparison with the main group, the increasing of points according to MMSE (Δ% + 4.2 %, p˂0.01).
 
Conclusions. 
The conducted research informs us about positive effects of the phenylpiracetam drug, which contribute to the improvement of treatment outcome among the patients with IHS in the recovery period

No comments:

Post a Comment